| SEC Fo | orm 4 |
|--------|-------|
|--------|-------|

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

## OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

| 1. Name and Address of Reporting Person <sup>*</sup><br>Flynn Daniel Lee           |               |                | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Deciphera Pharmaceuticals, Inc.</u> [ DCPH ] | (Checl                 | ationship of Reporting Pe<br>< all applicable)<br>Director<br>Officer (give title        | rson(s) to Issuer<br>10% Owner<br>Other (specify |
|--|---------------|----------------|---|------------------------|--|--|
| (Last) (First) (Middle)<br>C/O DECIPHERA PHARMACEUTICALS, INC.<br>200 SMITH STREET |               | ( )            | 3. Date of Earliest Transaction (Month/Day/Year)<br>01/16/2020  | - X                    | below)<br>Chief Scientifi  | below)   |
| (Street)<br>WALTHAM<br>(City)  | MA<br>(State) | 02451<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)  | 6. Indiv<br>Line)<br>X | vidual or Joint/Group Filir<br>Form filed by One Rej<br>Form filed by More the<br>Person | porting Person                                   |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction<br>Code (Instr.  |  |        |           |               | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|--|--|--------|-----------|---------------|---|---|---|
|                                 |  |   | Code V Amount (A) or<br>(D) Price Reported<br>Transaction(s)<br>(Instr. 3 and 4) |  |        | (1150. 4) |               |   |   |   |
| Common Stock                    | 01/16/2020                                 |   | М  |  | 10,106 | A         | \$3.95        | 34,606  | D   |   |
| Common Stock                    | 01/16/2020                                 |   | М  |  | 56,800 | A         | <b>\$6.13</b> | 91,406  | D   |   |
| Common Stock                    |  |   |  |  |        |           |               | 91,020  | Ι   | By Daniel<br>L. Flynn<br>Irrevocable<br>Trust                     |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   |     |        | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|-----|--------|--|--------------------|---|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A) | (D)    | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$3.95  | 01/16/2020                                 |   | М                            |   |     | 10,106 | (1)  | 09/26/2026         | Common<br>Stock   | 10,106                                 | \$0.00  | 29,444   | D  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$6.13  | 01/16/2020                                 |   | М                            |   |     | 56,800 | (2)  | 06/03/2027         | Common<br>Stock   | 56,800                                 | \$0.00  | 94,817   | D  |  |

### Explanation of Responses:

1. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates.

2. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates.

### Remarks:

#### /s/ Thomas P. Kelly, Attorney-01/21/2020

Date

\*\* Signature of Reporting Person

in-Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.